Societe Generale reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Thursday.

Several other research firms have also recently commented on AZN. Morgan Stanley restated an overweight rating and issued a GBX 5,600 ($75.50) target price on shares of AstraZeneca plc in a research report on Friday, June 23rd. UBS AG set a GBX 5,150 ($69.44) target price on shares of AstraZeneca plc and gave the stock a neutral rating in a research report on Tuesday, June 27th. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research report on Wednesday, June 21st. Kepler Capital Markets restated a buy rating and issued a GBX 5,500 ($74.15) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, Liberum Capital restated a buy rating and issued a GBX 5,500 ($74.15) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of GBX 5,041.09 ($67.97).

Shares of AstraZeneca plc (LON:AZN) opened at 4912.00 on Thursday. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The firm’s market cap is GBX 62.19 billion. The company has a 50-day moving average of GBX 4,574.46 and a 200-day moving average of GBX 4,884.61.

ILLEGAL ACTIVITY NOTICE: “AstraZeneca plc’s (AZN) “Buy” Rating Reiterated at Societe Generale” was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/24/astrazeneca-plcs-azn-buy-rating-reiterated-at-societe-generale.html.

The company also recently declared a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were issued a dividend of GBX 68.90 ($0.93) per share. The ex-dividend date was Thursday, August 10th. This represents a dividend yield of 1.35%.

In related news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were purchased at an average price of GBX 4,370 ($58.92) per share, for a total transaction of £1,704.30 ($2,297.83).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.